Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSTARLET: Shorter and Safer Treatment Regimens for Latent TB
NCT06498414Phase 3Recruiting
- Sponsor
- McGill University Health Centre
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of rifampicin, levofloxacin and rifapentine in Tuberculosis (TB) (3 arms), sponsored by McGill University Health Centre. Primary endpoint: Severe treatment-related Adverse Events. Started Jun 2025; status: recruiting.
02
Drugs
rifampicinlevofloxacinrifapentine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06498414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06498414.